Deadline Approaching: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Core Viewpoint - Nektar Therapeutics is facing a class action lawsuit due to alleged securities fraud, with a deadline for shareholders to file a lead plaintiff motion by May 5, 2026 [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Nektar made materially false and misleading statements regarding its business and the results of the Phase 2b REZOLVE-AA trial for its alopecia areata treatment, rezpegaldesleukin [3]. - The trial results announced on December 16, 2025, indicated a failure to reach statistical significance, attributed to the inclusion of ineligible patients [2][3]. - Following the announcement, Nektar's stock price dropped by $4.14, or 7.8%, closing at $49.16 per share [3]. Group 2: Investor Participation - Investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights and potentially participate in the class action [1][2][4]. - To be appointed as lead plaintiff, investors must meet certain legal requirements and must file their motion by the specified deadline [4].